GSE171945
Sequencing of chronic myeloid leukemia (CML) cell lines upon upregulation or downregulation of G0/G1 switch gene (G0S2)
Current treatment for CML involves tyrosine kinase inhibitors (TKIs), which turned it into a managable disease. In a transcriptional profile of TKI-resistant versus newly diagnosed CML patient samples, G0S2 was shown to be profoundly downregulated. Overall design: CML cell line (K562) was lentivirally transduced (shNT, shG0S2, pLVX G0S2, shATGL) and selected in the presence of puromycin. Resulting cells were treated with doxycycline (0.1 ug/ml, 72 h) to induce vector expression.